Zydus starts human dosing of its vaccine ?ZyCoV-D?
Begins Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D
? ZyCoV-D was found to be safe, immunogenic, well tolerated in the pre-clinical toxicity studies.
? The vaccine was able to elicit high level of neutralizing antibodies in animal studies.
Ahmedabad, July 15, 2020
Zydus, an innovation driven global healthcare company, today announced that the Adaptive Phase
I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D commenced today with the first human
dosing. The Adaptive Phase I/II dose escalation, multi-centric study will assess the safety, tolerability
and immunogenicity of the vaccine. The human dosing of the vaccine marks a key milestone since the
launching of the accelerated vaccine development programme for COVID-19 in February 2020.
Speaking on the development, Chairman, Zydus Cadila, Mr. Pankaj R. Patel said, ?This is an all important
step in our fight against COVID-19. We acknowledge the support of National Biopharma Mission,
BIRAC, Department of Biotechnology, Govt. of India and regulatory agencies ICMR and DCGI in the
development of ZyCoV-D vaccine candidate. We look forward to the Adaptive Phase I/IIclinical studies
and gathering important data on ZyCoV-D in the months ahead.?
In the Adaptive Phase I/ II clinical trials, Zydus will be enrolling over 1000 subjects across multiple
clinical study sites in India. The Company has already manufactured clinical GMP batches of the vaccine
candidate for the clinical trials.
About ZyCoV-D
In the pre-clinical phase, the vaccine was found to elicit a strong immune response in multiple animal
species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to
neutralize the wild type virus in virus neutralization assay indicating the protective potential of the vaccine
candidate. No safety concerns were observed for the vaccine candidate in repeat dose toxicology studies
by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended
human dose was found to be safe, well tolerated and immunogenic.
With ZyCoV-D, the Company has successfully established the DNA vaccine platform in the country using
non-replicating and non-integrating plasmid carrying the gene of interest making it very safe. Further, no
vector response and with absence of any infectious agent, the platform provides ease of manufacturing
the vaccine with minimal biosafety requirements (BSL-1). The platform is also known to show much
improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest
Press Release
Press Release Press Release
Press Release
Press Release Press Release
Press Release Press Re?lease
Cadila Healthcare Limited
Regd. Office : ?Zydus Corporate Park?, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India.
Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com
CIN : L24230GJ1995PLC025878
For further information please contact :
The Corporate Communications Department
regions of the country. Furthermore, the platform can be rapidly used to modify the vaccine in couple of
weeks in case the virus mutates to ensure that the vaccine still elicits protection.
About Zydus
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures
and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics,
and vaccines.
Zydus? Vaccine research programme
Vaccine Technology Centre of Zydus Cadila has wide range of capabilities in developing and manufacturing
viral, toxoid, polysaccharide, conjugate and other subunit vaccines for unmet needs. In fact, Zydus was
the first company in India to develop and indigenously manufacture the vaccine to combat Swine Flu
during the pandemic in 2010. In past, it has also indigenously developed numerous vaccines successfully
including tetravalent seasonal influenza vaccine (first company in India to indigenously develop and
commercialize), Inactivated Rabies vaccine (WHO Prequalified), Varicella vaccine (first Indian company
to indigenously develop and receive market authorization), Measles containing vaccines (MR, MMR,
Measles), Typhoid conjugate vaccine, pentavalent vaccine (DPT-HepB-Hib) etc to name a few. The
company also has a strong pipeline of vaccines like Measles-Mumps-Rubella-Varicella (MMRV), Human
papillomavirus vaccine, Hepatitis A, Hepatitis E vaccines which are at various stages of development.